Clinical trials. Rituximab for maintenance of remission in AAV
- PMID: 25599619
- DOI: 10.1038/nrneph.2014.254
Clinical trials. Rituximab for maintenance of remission in AAV
Abstract
Maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) should reduce rates of relapse with minimal toxicity. The MAINRITSAN trial—the first randomized controlled trial to compare the efficacies of rituximab and azathioprine in AAV remission maintenance— has demonstrated a superior outcome using rituximab. These data have important implications for the management of AAV.
Comment on
-
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231. N Engl J Med. 2014. PMID: 25372085 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources